Target intelligence / Profile preview

ADP-ribosylation factor-like 16 pseudogene

Molecular classification
Pseudogene, Other
01

Overview

ADP-ribosylation factor-like 16 pseudogene is a non-protein-coding genomic locus related to the ARL16 gene, which encodes a GTP-binding protein of the ADP-ribosylation factor-like family[4]. As a pseudogene, it harbors sequence similarity to its parent gene but has accumulated disabling mutations, preventing the production of a functional protein[2][5][7]. Pseudogenes may sometimes be transcribed and can play roles in the regulation of gene expression, but direct evidence for such function in the ARL16 pseudogene is lacking. It is not recognized as a therapeutic target, does not participate in canonical molecular pathways, and has no established biological or disease associations[2][5][7]. Pseudogenes are classified as unitary, unprocessed (duplicated), or processed pseudogenes by their genesis and structure[2][5]. The ARL16 protein (gene: ENSG00000214087), not the pseudogene, is a member of the ARF-like GTPases and has described cellular functions, but these do not apply to the pseudogene locus[4]. Catalogs of human pseudogenes, including ARF and ARL family members, exist but do not attribute functions, biomarkers, or druggability to the pseudogene entries[7]. This target is not a therapeutic target, nor is it a functional receptor, enzyme, or transporter. The submitted target is "incorrect" if the intended query is to find actionable drug targets or functional genes, as ARL16 pseudogene is nonfunctional and not druggable[2][5][7].

Other names
ARL16 pseudogene
02

Mechanism of action

None; pseudogenes do not encode active proteins or receptors for pharmacological targeting.

03

Biological functions

Pseudogenes do not encode functional proteins and typically do not participate directly in canonical biological processes; however, some pseudogenes can act in gene regulation as microRNA decoys or transcriptional regulators in rare cases.Other
04

Disease associations

No specific disease associations are documented for ARL16 pseudogenes; direct disease relevance is not established.Other
05

Safety considerations

None; pseudogenes are not themselves drug targets and pose no direct therapeutic challenges.
06

Interacting drugs

None known; pseudogenes are not established as direct drug targets.
07

Biomarkers

None established; ARL16 pseudogene is not used as a biomarker.

Beyond the preview

Go deeper on ADP-ribosylation factor-like 16 pseudogene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADP-ribosylation factor-like 16 pseudogene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call